KAEDI   Report issue

Academic/Hospital Phase 1
Founded: Jiangsu China (2015)

Organization Overview

First Clinical Trial
2018
NCT03854994
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2022

Timeline

NOW
  • Now

Alternative names

KAEDI

Active Ingredients

Drugs in Phase 1 Trials (5)

cd19 car-t cells (1 trial)

kd025 (1 trial)

kd-025 car-t cells (1 trial)

kd-496 (1 trial)

nkg2d car-t cell (2 trials)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Carcinoma, Hepatocellular (Phase 1)

Glioblastoma (Phase 1)

Leukemia (Phase 1)

Leukemia, Lymphoid (Phase 1)

Lymphoma (Phase 1)

Lymphoma, B-Cell (Phase 1)

Medulloblastoma (Phase 1)

Precursor Cell Lymphoblastic Leukemia-Lymphoma (Phase 1)

Overview

  • Highest Phase: Phase 1
  • # of Trials: 6
  • # of Trial APIs: 5